Scientists unravel the structure of common bacterial wall-building protein, setting stage for new antibacterial therapies
The wall that surrounds bacteria to shield them from external assaults has long been a tantalizing target for drug therapies. Indeed, some of modern medicine’s most reliable antibiotics disarm harmful bacteria by disrupting the proteins that build their protective armor.
<iframe src=”https://player.vimeo.com/video/262243190″ width=”640″ height=”360″ frameborder=”0″ webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>
For decades, scientists knew of only one wall-making protein family. Then, in 2016, a team of Harvard Medical School scientists discovered that a previously unsuspected family of proteins that regulate cell division and cell shape had a secret skill: building bacterial walls.
Now, in another scientific first described March 28 in Nature, members of the same research team have revealed the molecular building blocks—and a structural weak spot—of a key member of that family.
“Our latest findings reveal the molecular structure of RodA and identify targetable spots where new antibacterial drugs could bind and subvert its work,” said study senior investigator Andrew Kruse, associate professor of biological chemistry and molecular pharmacology at Harvard Medical School.
The newly profiled protein, RodA, belongs to a family collectively known as SEDS proteins, present in nearly all bacteria. SEDS” near-ubiquity renders these proteins ideal targets for the development of broad-spectrum antibiotics to disrupt their structure and function, effectively neutralizing a range of harmful bacteria.
A weak link
In their earlier work, the scientists showed that RodA builds the cellular wall by knitting together large sugar molecules with clusters of amino acids. Once constructed, the wall encircles the bacterium, keeping it structurally intact, while repelling toxins, drugs and viruses.
The latest findings, however, go a step further and pinpoint a potential weak link in the protein’s makeup.
Specifically, the protein’s molecular profile reveals structural features reminiscent of other proteins whose architecture Kruse has disassembled. Among them, the cell receptors for the neurotransmitters acetylcholine and adrenaline, which are successfully targeted by medications that boost or stem the levels of these nerve-signaling chemicals to treat a range of conditions, including cardiac and respiratory diseases.
One particular feature caught the scientists’ attention—a pocket-like cavity facing the outer surface of the protein. The size and shape of the cavity, along with the fact that it is accessible from the outside, make it a particularly appealing drug target, the researchers said.
“What makes us excited is that this protein has a fairly discrete pocket that looks like it could be easily and effectively targeted with a drug that binds to it and interferes with the protein’s ability to do its job,” said study co-senior author David Rudner, professor of microbiology and immunobiology at Harvard Medical School.
In a set of experiments, researchers altered the structure of RodA in two bacterial species—the textbook representatives of the two broad classes that make up most of disease-causing bacteria. One of them was Escherichia coli, which belongs to a class of organisms with a double-cell membrane known as gram-negative bacteria, so named due to a reaction to staining test used in microbiology. The other bacterium was Bacillus subtilis, a single-membrane organism that belongs to so-called gram-positive bacteria.
When researchers induced even mild alterations to the structure of RodA’s cavity, the protein lost its ability to perform its work. E. coli and B. subtilis cells with disrupted RodA structure rapidly enlarged and became misshapen, eventually bursting and leaking their contents.
“A chemical compound—an inhibitor—that binds to this pocket would interfere with the protein’s ability to synthesize and maintain the bacterial wall,” Rudner said. “That would, in essence, crack the wall, weaken the cell and set off a cascade that eventually causes it to die.”
Additionally, because the protein is highly conserved across all bacterial species, the discovery of an inhibiting compound means that, at least in theory, a drug could work against many kinds of harmful bacteria.
“This highlights the beauty of super-basic scientific discovery,” said co-investigator Thomas Bernhardt, professor of microbiology and immunobiology at Harvard Medical School. “You get to the most fundamental level of things that are found across all species, and when something works in one of them, chances are it will work across the board.”
Solving for X
To determine RodA’s structure, scientists used a visualization technique known as X-ray crystallography, which reveals the molecular architecture of protein crystals based on a pattern of scattered X-ray beams. The technique requires two variables—the intensity of scattered X-rays and a so-called “phase angle,” a property related to the configuration of the atoms in a protein. The latter is measured indirectly, typically by using a closely related protein as a substitute to calculate the variable.
In this case, however, the team had on its hands a never-before-described protein with no known molecular siblings.
“In most cases you can use a related structure and bootstrap to a solution,” Kruse said. “In this case, we couldn’t do that. We had to predict what RodA looked like without any prior information about it.”
They needed a new way to solve for X.
In a creative twist, researchers turned to evolution and predictive analytics. Working with Debora Marks, assistant professor of systems biology at Harvard Medical School, they constructed a virtual model of the RodA’s folding pattern by analyzing the sequences of its closest evolutionary cousins.
The success of this “roundabout” approach, researchers said, circumvents a significant hurdle in field of structural biology and can open the doors toward defining the structures of many more newly discovered proteins.
“These insights underscore the importance of creative crosspollination among scientists from multiple disciplines and departments,” said study first author Megan Sjodt, a research fellow in biological chemistry and molecular pharmacology at Harvard Medical School. “We believe our results set the stage for subsequent work toward the discovery and optimization of new classes of antibiotics.”
Learn more: A Chink in Bacteria’s Armor
The Latest on: Antibiotics
via Google News
The Latest on: Antibiotics
- Animal Antibiotics And Antimicrobials Market 2020 Capacity Utilization Rate, Ex-Factory Price, Revenue and Gross Margin Analysis to 2026on May 10, 2020 at 1:15 am
Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Animal Antibiotics And Antimicrobials Market” report provides valuable information regarding new products in the ...
- New mums with non-routine births to be given antibiotics for first timeon May 9, 2020 at 8:30 pm
Thousands of new mums will be spared pain and long-term health problems after NHS guidelines were changed. Women who experience non-routine births will now be given routine antibiotics for the first ...
- Hygiene reduces the need for antibiotics by up to 30%on May 8, 2020 at 12:19 am
According to a new Position Paper published in the American Journal of Infection Control (AJIC) online, improved everyday hygiene practices, such as hand-washing, reduces the risk of common infections ...
- Antibiotics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class ; Action Mechanism, and Geographyon May 7, 2020 at 2:52 pm
The antibiotics was valued at US$ 43,348.38 million in 2019 and is projected to reach US$ 56,351.33 million by 2027; it is expected to grow ...
- Why bacteria's resistance to antibiotics is a problem in a viral pandemicon May 6, 2020 at 9:28 am
Each year a particular kind of infection kills more than 35,000 people in the United States. Those deaths are caused by antibiotic-resistant bacteria.
- UKZN professor warns against use of antibiotics to treat Covid-19 patientson May 6, 2020 at 3:28 am
Durban - South African Research Chair in Antibiotic Resistance, Professor Sabiha Essack is calling on healthcare providers to exercise prudence when prescribing antibiotics to Covid-19 patients.
- Antibiotics Market 2020 Size, Share, Growth, Demand, Application, Types, Top Key Players and Current Business Trends by 2026on May 6, 2020 at 1:04 am
Advanced report on ' Antibiotics market' Added by Analytical Research Cognizance, offers details on current and future growth ...
- Watchdog: HHS Failed To Properly Incentivize Development Of Antibiotics In Era Of Superbugson May 5, 2020 at 8:45 pm
Read about the biggest pharmaceutical development and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.
- Dr. Cornelius Clancy: To combat coronavirus, we may need more antibioticson May 5, 2020 at 11:00 am
Cornelius Clancy, M.D., is an associate professor of medicine and director of the XDR Pathogen Lab at the University of Pittsburgh. The coronavirus infects and kills more Americans each day. The ...
via Bing News